Following its recent agreement with GlaxoSmithKline PLC to fund development of new antibiotics for resistant infections and potential bioterror agents, the U.S. Biomedical Advanced Research and Development Authority has signed up another private-sector partner. On May 28, it announced a potential five-year, $58 million contract with Cempra Inc. to test its investigational antibiotic solithromycin in pediatric populations and as a treatment for bioterror-threat pathogens.
Solithromycin, a fourth-generation macrolide antibiotic in the fluoroketolide family, is in Phase III testing for community-acquired bacterial pneumonia (CABP) in...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?